MARKET

QURE

QURE

Uniqure
NASDAQ
14.73
-0.04
-0.27%
Pre Market: 15.00 +0.27 +1.83% 07:26 03/31 EDT
OPEN
14.67
PREV CLOSE
14.77
HIGH
15.28
LOW
14.51
VOLUME
24
TURNOVER
0
52 WEEK HIGH
71.50
52 WEEK LOW
7.76
MARKET CAP
921.06M
P/E (TTM)
-4.2570
1D
5D
1M
3M
1Y
5Y
1D
Passage Bio initiated with an Outperform at Oppenheimer
TipRanks · 17h ago
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
PR Newswire · 17h ago
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
PR Newswire · 20h ago
U.S. Chess Champion Dips Below the S&P as Tech Stock Picks Falter
TipRanks · 1d ago
Weekly Report: what happened at QURE last week (0323-0327)?
Weekly Report · 1d ago
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
PR Newswire · 1d ago
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
PR Newswire · 3d ago
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit
PR Newswire · 3d ago
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers Uniqure NV stock information, including NASDAQ: QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.